Kimberly Sanders

As VP US Vaccines (Sales) for Global Fortune 500 leader GSK (GlaxoSmithKline), Kim Sanders is driving the rebirth of GSK’s $6B vaccine business after massive COVID business disruptions. Kim was an instrumental leader in the most successful vaccine launch in GSK’s history, expanding Shingrix into a $5B brand and becoming the cornerstone of GSK’s corporate strategy to become the world’s leading vaccine company. Throughout her 20+ year career, Kim has a track record of driving teams to #1 rankings, utilizing her high energy and empathetic approach to deliver growth. Kim has built a reputation as a trusted board advisor, influencing and guiding C-suite leaders and board members through business challenges including billion dollar global vaccine launches and COVID-related business challenges. Kim has a passion for public health and is proud to deliver cutting-edge vaccines to the public while working to alleviate the national crisis of lowered childhood vaccination rates.